Insulin-like growth factor-I has different effects on myogenin induction and cell cycle progression in human alveolar and embryonal rhabdomyosarcoma cells

International Journal of Oncology

Volumn 31, Issue 1, 2007, Pages 41-47

  Tsuchiya, Kunihiko ^a   Hosoi, Hajime ^a   Misawa Furihata, Akiko ^a   Houghton, Peter J ^b   Sugimoto, Tohru ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

4E BP1; Cell cycle progression; IGF I; Myogenin; Rhabdomyosarcoma

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTINEOPLASTIC ANTIBIOTIC; IMIDAZOLE DERIVATIVE; MAMMALIAN TARGET OF RAPAMYCIN; MONOCLONAL ANTIBODY; MYOGENIN; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; RAPAMYCIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ARTICLE; CELL CYCLE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; EMBRYONAL RHABDOMYOSARCOMA; HUMAN; METABOLISM; MUSCLE DEVELOPMENT; PROTEIN SYNTHESIS; RHABDOMYOSARCOMA; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; CELL CYCLE; CELL LINE, TUMOR; HUMANS; IMIDAZOLES; INSULIN-LIKE GROWTH FACTOR I; MUSCLE DEVELOPMENT; MYOGENIN; PROTEIN BIOSYNTHESIS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PYRIDINES; RECEPTOR, IGF TYPE 1; RHABDOMYOSARCOMA, ALVEOLAR; RHABDOMYOSARCOMA, EMBRYONAL; SIROLIMUS;

EID: 34548593239     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.31.1.41     Document Type: Article

References (43)

1. Enzinger FM and Weiss SW: Soft Tissue Tumor. 2nd edition. Mosby, St. Louis, pp448-488, 1989.
2. Newton WA, Gehan EA and Webber BL: Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification - an Intergroup Rhabdomyosarcoma Study. Cancer 76: 1073-1085, 1995.
3. Galili N, Davis RJ, Fredericks WJ, Mukhopadhyay S, Rauscher FJ III, Emanuel BS and Rovera G: Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet 5: 230-235, 1993. (Pubitemid 23330384)
4. Shapiro DN, Sublett JE, Li B, Downing JR and Naeve CW: Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. Cancer Res 53: 5108-5101, 1993.
5. Anderson J, Gordon T, McManus A, Mapp T, Gould S, Kelsey A, McDowell H, Pinkerton R, Shipley J and Pritchard-Jones K: UK Children's Cancer Study Group (UKCCSG) and the UK Cancer Cytogenetics Group. Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome? Br J Cancer 85: 831-835, 2001.
6. Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM, Bridge JA, Crist WM, Triche TJ and Barr FG: PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol 20: 2672-2679, 2002.
7. Khan J, Bittner ML, Saal LH, Teichmann U, Azorsa DO, Gooden GC, Pavan WJ, Trent JM and Meltzer PS: cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Proc Natl Acad Sci USA 96: 13264-13269, 1999.
8. Weintraub H: The MyoD family and myogenesis: redundancy, networks, and thresholds. Cell 75: 1241-1244, 1993.
9. Arnold HH and Braun T: Targeted inactivation of myogenic factor genes reveals their role during mouse myogenesis. Int J Dev Biol 40: 345-353, 1996.
10. Davis RL, Weintraub H and Lassar AB: Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell 51: 987-1000, 1987.
11. Wright WE, Sassoon DA and Lin VK: Myogenin, a factor regulating myogenesis, has a domain homologous to MyoD. Cell 56: 607-617, 1989.
12. Braun T, Buschhausen-Denker G, Bober E, Tannich E and Arnold HH: A novel human muscle factor related to but distinct from MyoD1 induces myogenic conversion in 10T1/2 fibroblasts. EMBO J 8: 701-709, 1989. (Pubitemid 19273240)
13. Hasty P, Bradley A, Morris JH, Edmondson DG, Venuti JM, Olson EN and Klein WH: Muscle deficiency and neonatal death in mice with a target mutation in the myogenin gene. Nature 364: 501-506, 1993.
14. Nabeshima Y, Hanaoka K, Hayasaka M, Esumi E, Li S and Nonaka I: Myogenin gene disruption results in perinatal lethality because of severe muscle defect. Nature 364: 532-535, 1993.
15. Florini JR, Ewton DZ and Roof SL: Insulin-like growth factor-I stimulates terminal myogenic differentiation by induction of myogenin gene expression. Mol Endocrinol 5: 718-724, 1991.
16. Xu Q and Wu Z: The insulin-like growth factor-phosphatidylinositol 3-kinase-Akt signaling pathway regulates myogenin expression in normal myogenic cells but not in rhabdomyosarcoma- derived RD cells. J Biol Chem 275: 36750-36757, 2000.
17. Cuenda A and Cohen P: Stress-activated protein kinase-2/p38 and a rapamycin-sensitive pathway are required for C2C12 myogenesis. J Biol Chem 274: 4341-4346, 1999. (Pubitemid 29090970)
18. Kumar S, Perlham E, Harris CA and Tsokos M: Myogenin is a specific marker for rhabdomyosarcoma: An immunohistochemical study in paraffin-embedded tissues. Mod Pathol 13: 988-993, 2000.
19. Dias P, Chen B, Dilday B, Palmer H, Hosoi H, Singh S, Wu C, Li X, Thompson J, Parham D, Qualman S and Houghton P: Strong immunostaining for myogenin in rhabdomyosarcoma is significantly associated with tumors of the alveolar subclass. Am J Pathol 156: 399-408, 2000. (Pubitemid 30643794)
20. Cessna MH, Zhou H, Perkins SL, Tripp SR, Layfield L, Daines C and Coffin CM: Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics. Am J Surg Pathol 25: 1150-1157, 2001. (Pubitemid 32777714)
21. Hostein I, Andraud-Fregeville M, Guillou L, Terrier-Lacombe MJ, Deminiere C, Ranchere D, Lussan C, Longavenne E, Bui NB, Delattre O and Conindre JM: Rhabdomyosarcoma: value of myogenin expression analysis and molecular testing in diagnosing the alveolar subtype: an analysis of 109 paraffin-embedded specimens. Cancer 101: 2817-2824, 2004.
22. Maloney EK, McLaughlin JL, Dagdigian NE, Garrett LM, Connors KM, Zhou XM, Blattler WA, Chittenden T and Singh R: An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 63: 5073-5083, 2003.
23. El-Badry OM, Minniti C, Kohn EC, Houghton PJ, Daughaday WH and Helman LJ: Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ 1: 325-331, 1990.
24. Toretsky JA and Helman LJ: Involvement of IGF-II in human cancer. J Endocrinol 149: 367-372, 1996.
25. Kalebic T, Tsokos M and Helman LJ: In vivo treatment with antibody against IGF-I receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2. Cancer Res 54: 5531-5541, 1994.
26. Shapiro DN, Jones BG, Shapiro LH, Dias P and Houghton PJ: Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma. J Clin Invest 94: 1235-1242, 1994.
27. Hosoi H, Dilling MB, Lui LN, Shikata T, Sekulic A, Abraham RT, Lawrence JC Jr and Houghton PJ: Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol Pharmacol 54: 815-824, 1998.
28. Hosoi H, Dilling MB, Shikata T, Lui LN, Shu L, Ashmun RA, Germain GS, Abraham RT and Houghton PJ: Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res 59: 886-894, 1999. (Pubitemid 29086744)
29. Luo W, Sharif TR and Sharif M: Substance P-induced mitogenesis in human astrocytoma cells correlates with activation of the mitogen-activated protein kinase signaling pathway. Cancer Res 56: 4983-4991, 1996.
30. Pier LP: Induction of terminal differentiation by constitutive activation of p38MAP kinase in human rhabdomyosarcoma cells. Gene Dev 14: 574-584, 2000.
31. Wu Z, Woodring PJ, Bhakta KS, Tamura K, Wen F, Feramisco JR, Karin M, Wang JY and Puri PL: p38 and extracellular signal-regulated kinases regulate the myogenic program at multiple steps. Mol Cell Biol 20: 3951-3964, 2000.
32. Yael T and Eyal B: Phosphoinositide 3-kinase induces the transcriptional activity of MEF2 protein during muscle differentiation. J Biol Chem 275: 34424-34432, 2000.
33. Lee J, Hong F, Kwon S, Kim SS, Kim DO, Kang HS, Lee SJ, Ha J and Kim SS: Activation of p38 MAPK induces cell cycle arrest via inhibition of Raf/ERK pathway during muscle differentiation. Biochem Biophys Res Commun 298: 765-771, 2002.
34. Gingras AC, Raught B and Sonenberg N: eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 68: 913-963, 1999. (Pubitemid 29449212)
35. Jefferies HB, Reinhard C, Kozma SC and Thomas G: Rapamycin selectively represses translation of the 'polypyrimidine tract' mRNA family. Proc Natl Acad Sci USA 91: 4441-4445, 1994.
36. Terada N, Patel HR, Takase K, Kohno K, Nairn AC and Gelfand EW: Rapamycin selectively inhibits translation of mRNAs encoding elongation factors and ribosomal proteins. Proc Natl Acad Sci USA 91: 11477-11481, 1994. (Pubitemid 24356367)
37. Iiboshi Y, Papst PJ, Kawasome H, Hosoi H, Abraham RT, Houghton PJ and Terada N: Amino acid-dependent control of p70s6k: Involvement of tRNA aminoacylation in the regulation. J Biol Chem 274: 1092-1099, 1999.
38. Sumitani S, Goya K, Testa RJ, Kouhara H and Kasayama S: Akt1 and Akt2 differently regulate muscle creatine kinase and myogenin gene transcription in insulin-induced differentiation of C2C12 myoblasts. Endocriology 143: 820-828, 2002.
39. Coolican SA, Samuel DS, Ewton DZ, McWade FJ and Florini JR: The mitogenic and myogenic actions of insulin-like growth factors utilize distinct signaling pathways. J Biol Chem 272: 6653-6662, 1997.
40. Jiang BH, Zheng JZ and Vogt PK: An essential role of phosphatidylinositol3-kinase in myogenic differentiation. Proc Natl Acad Sci USA 95: 14179-14183, 1998.
41. Jiang BH, Aoki M, Zheng JZ, Li J and Vogt PK: Myogenic signaling of phosphatidylinositol 3-kinase requires the serine-threonine kinase Akt/protein kinase B. Proc Natl Acad Sci USA 96: 2077-2081, 1999.
42. Canicio J, Gallardo E, Illa I, Testar X, Palacin M, Zorzano A and Kaliman P: p70 S6 kinase activation is not required for insulin-like growth factor-induced differentiation of rat, mouse, or human skeletal muscle cells. Endocrinology 139: 5042-5049, 1998. (Pubitemid 28533452)
43. Shu L, Zhang X and Houghton PJ: Myogenic differentiation is dependent on both the kinase function and the N-terminal sequence of mammalian target of rapamycin. J Biol Chem 277: 16726-16732, 2002. Epub Mar 1 2002.